Fetal hydrops and the Incremental yield of Next generation sequencing over standard prenatal Diagnostic testing ( FIND) study: prospective cohort study and meta‐analysis

Accepted/In Press date: 29 March 2021

e-pub ahead of print date: 13 April 2021

Published date: October 2021

Additional Information: Funding Information: R.Y.E. and J.L. report grants from the Health Innovation Challenge Fund during the conduct of the PAGE study. D.J.M. reports grants for travel expenses from Congenica to attend educational symposia during the conduct of the PAGE study. M.E.H. reports grants from the Wellcome Trust and the UK Government Department of Health during the conduct of the study and personal fees from Congenica, outside of the submitted work. M.D.K. is a member of Illumina's International Perinatal Advisory Group (but receives no payment for this) and is the Fetal Medicine Representative for the Central and South GLH. He is also the Royal College of Obstetricians and Gynaecologists' (RCOG) representative on the Joint Colleges Committee of Genomic and Genetic Medicine and the RCOG Genomic Taskforce. E.R.M. has received travel expenses, accommodation and consultant fees for participating in an Illumina International Advisory Group after completion of the PAGE study. M.D.K. is funded through the Department of Health, Wellcome Trust and Health Innovation Challenge Fund (award number HICF‐R7‐396) for the PAGE and PAGE2 research studies completed in August 2019. L.S.C. was funded partially by the same group in relation to the PAGE study. R.J.W. receives funding from Illumina and NIH for research. M.E.N. has been funded from Ultragenyx and the NIH for research relevant to included cases. Funding Information: The PAGE study was supported by a Health Innovation Challenge from the UK Department of Health and Wellcome Trust (no. HICF-R7-396). We are grateful to Jane Fisher from?Antenatal Results and Choices and to Michael Parker of The Ethox Centre, Nuffield Department of Population Health and Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK, for their valuable input to the study. We are also grateful to the members of the PAGE study clinical review panel. L.S.C., a NIHR Senior Investigator, is funded partially by the National Institute for Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, London, UK. E.R.M. acknowledges support from NIHR Cambridge Biomedical Research Centre, Cambridge, UK (NIHR Senior Investigator Award). The University of Cambridge, Cambridge, UK, has received salary support with regard to E.R.M. from the UK National Health Service (NHS) in the East of England through the Clinical Academic Reserve. The views expressed herein are those of the authors and not necessarily those of the NIHR, NHS or Department of Health. R.Y.E. and J.L. report grants from the Health Innovation Challenge Fund during the conduct of the PAGE study. D.J.M. reports grants for travel expenses from Congenica to attend educational symposia during the conduct of the PAGE study. M.E.H. reports grants from the Wellcome Trust and the UK Government Department of Health during the conduct of the study and personal fees from Congenica, outside of the submitted work. M.D.K. is a member of Illumina's International Perinatal Advisory Group (but receives no payment for this) and is the Fetal Medicine Representative for the Central and South GLH. He is also the Royal College of Obstetricians and Gynaecologists' (RCOG) representative on the Joint Colleges Committee of Genomic and Genetic Medicine and the RCOG Genomic Taskforce. E.R.M. has received travel expenses, accommodation and consultant fees for participating in an Illumina International Advisory Group after completion of the PAGE study. M.D.K. is funded through the Department of Health, Wellcome Trust and Health Innovation Challenge Fund (award number HICF-R7-396) for the PAGE and PAGE2 research studies completed in August 2019. L.S.C. was funded partially by the same group in relation to the PAGE study. R.J.W. receives funding from Illumina and NIH for research. M.E.N. has been funded from Ultragenyx and the NIH for research relevant to included cases. Funding Information: The PAGE study was supported by a Health Innovation Challenge from the UK Department of Health and Wellcome Trust (no. HICF‐R7‐396). We are grateful to Jane Fisher from Antenatal Results and Choices and to Michael Parker of The Ethox Centre, Nuffield Department of Population Health and Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK, for their valuable input to the study. We are also grateful to the members of the PAGE study clinical review panel. L.S.C., a NIHR Senior Investigator, is funded partially by the National Institute for Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, London, UK. E.R.M. acknowledges support from NIHR Cambridge Biomedical Research Centre, Cambridge, UK (NIHR Senior Investigator Award). The University of Cambridge, Cambridge, UK, has received salary support with regard to E.R.M. from the UK National Health Service (NHS) in the East of England through the Clinical Academic Reserve. The views expressed herein are those of the authors and not necessarily those of the NIHR, NHS or Department of Health. Publisher Copyright: © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Keywords: exome sequencing, fetus, hydrops, next-generation sequencing, non-immune hydrops fetalis, prenatal diagnosis

Local EPrints ID: 449248

URI: http://eprints.soton.ac.uk/id/eprint/449248

DOI: doi:10.1002/uog.23652

ISSN: 0960-7692

PURE UUID: ef3e8dbe-dd37-4651-9bbd-0bab3398606c

ORCID for Jenny Lord: orcid.org/0000-0002-0539-9343

Date deposited: 20 May 2021 16:32

Last modified: 17 Mar 2024 06:34